Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes.
OBJECTIVE
To evaluate the performance of FINDRISC as a screening tool for prediabetes - impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) and undetected diabetes (UDD) in subjects at risk of developing diabetes.


METHODS
2169 subjects with at least one risk factor for diabetes completed the FINDRISC questionnaire and underwent an oral glucose tolerance test. FINDRISC performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC).


RESULTS
56.6% of subjects demonstrated normal glucose tolerance (NGT), 14.5% - IFG, 11.4% - IGT and 17.5% - UDD. NGT group demonstrated mean FINDRISC 10.1±3.4, IFG group - 13.8±4.3 (p<0.0001 vs. NGT), IGT group - 14.4±5.4 (p<0.0001 vs. NGT) and UDD group - 15.5±4.8 (p<0.0001 vs. NGT and IFG, p<0.01 vs. IGT). The AUC-ROC was 0.70 (95% CI 0.67-0.73) for UDD and 0.71 (95% CI 0.69-0.73) for undetected prediabetes and diabetes. The FINDRISC cut-off value of 10 to identify both prediabetes and diabetes had sensitivity of 84% and specificity of 61%.


CONCLUSIONS
FINDRISC is a feasible, non-invasive and useful tool for identifying subjects at risk for undetected diabetes and prediabetes. Laboratory screening should be performed in subjects with FINDRISC higher than 10.
Department of Diabetology, Clinical Center of Endocrinology, University Hospital of Endocrinology, Medical University, 2, Zdrave Str, 1431 Sofia, Bulgaria. tankova@iname.com
Tsvetalina
T
Tankova
Nevena
N
Chakarova
Iliana
I
Atanassova
Lilia
L
Dakovska
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood* / Q000175:diagnosis*; D005215:Fasting / Q000097:blood*; D005260:Female; D018149:Glucose Intolerance / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose